Sun, Feb 1, 2015, 4:01 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Metropolitan Health Networks Inc. Message Board

dickmilde 6 posts  |  Last Activity: Jan 17, 2015 11:27 AM Member since: Jan 2, 2000
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Go to the SLP web site, click on the investors tab and select "Conference Calls".
    Ted Grasela. the president of acquired company Cognigen, provides an excellent presentation. It's good to see that he has come up to speed in such a short time. He seems to understand the nuts and bolts of the SLP business very well and will certainly make a positive contribution to the continued growth of the combined business. This business combination looks like a good move for SLP and provides an excellent opportunity for continued growth. SLP will be a larger company next year and patient investors should be well rewarded.

  • Reply to

    New products soon to come??

    by dvb6000 Jan 13, 2015 1:27 PM
    dickmilde dickmilde Jan 13, 2015 9:53 PM Flag

    There is a PowerPoint presentation filed at the SEC web site that lists some of the new products they are working on.

  • Reply to

    A big THANK YOU to Walt and hs dedicated staff.

    by dickmilde Dec 29, 2014 4:40 PM
    dickmilde dickmilde Dec 31, 2014 9:54 AM Flag

    I've been invested in SLP since the early 2000's. Split adjusted the shares were around 25 cents. SLP is very consistent in growing sales and earnings, so as long as that continues there shouldn't be a "leveling off" Yes, there will be ups and downs but keep your eye on the big picture.

  • Up 4% today on a good volume increase. That's a good way to get ready for another year of positive results. SLP continues to all the right stuff...The team at Simulations-Plus continues to find ways to make the company more valuable. I expect we will see a larger company next year which should result in a higher valuation.

  • Reply to

    Annual sales growth 13.8% 4th Qtr growth 27.4%

    by dickmilde Nov 29, 2014 9:41 PM
    dickmilde dickmilde Dec 2, 2014 10:12 AM Flag

    It looks like that hasn't been updated yet... I'm expecting a little higher, closer to $4 million but, we don't know anything about seasonality yet for Cognigen,

  • It's a good time to be invested in SLP! The recent Cogingen merger will advance gross sales by almost 45% so we should see sales levels in excess of $18 Million per year. And there is a lot of stuff going on that is getting us into new markets... The new MembranePlus software, Dow Chemical Licenses Simulations Plus Software to Assist with Toxicology and Environmental Research, the AEROModeler and much more.
    " We believe the fundamental industry shift continues".
    The drug discovery business has hit a brick wall and can no longer use the old brute force method... They are in desperate need of help with new technologies to keep them going, and SLP is providing that need. Those that don't embrace the new way by using computer software to streamline their business will be left behind. As SLP customers sign up for new offerings and the enhancements to the existing tools, new customers will have to acquire the software as well in order to remain competitive. Also, It's not difficult to understand that if the FDA is using an SLP product to evaluate submissions that the company looking for FDA approval should be using SLP software ahead of any submission.
    I've been an investor since the dotcom bust around 2000-2001 and I've watched SLP grow from a market cap of less than $4 Million to over $100 Million ( that's called a 25 bagger ) and we are taking another big jump with the Cognigen acquisition. It's an exciting time to be here... I still have all my shares :-)

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.